bluuebunny/crossref_metadata_2025 huggingface dataset:
Usability of exergames as a home-based balance training tool for older adults: protocol for a systematic review
Authors: Medeiros Candice Simões Pimenta de , Santos Jaiana Xavier , Restrepo Daniela Ramirez , Araújo Farias Luanna Barbara , Pacheco Thaiana Barbosa Ferreira , Cavalcanti Fabrícia Azevêdo da Costa
Published: April 2023

Introduction

Exergames are used in the clinical practice of geriatric rehabilitation to increase physical activity levels and motivate players/patients. Their use in the home environment makes it possible to perform fun, engaging and interactive training with a large number of repetitions, thereby reducing the negative repercussions of postural imbalance in older adults. The aim of this systematic review is to collate and analyse evidence on the usability of exergames as a tool for home-based balance training for older adults.

Methods and analysis

We will include randomised controlled trials involving healthy older adults (aged 60 years or older) who are described as having impaired static or dynamic balance using any subjective or objective assessment criteria. We will search Web of Science, MEDLINE, Embase, Scopus, ScienceDirect and the Cochrane Library from database inception to December 2022. ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform and ReBEC will be searched for ongoing or unpublished trials. Two independent reviewers will screen the studies and extract the data. The findings will be presented in the text and tables, and if possible, relevant meta-analyses will be performed. The risk of bias and the quality of evidence will be assessed based on the recommendations of the Cochrane Handbook and Grading of Recommendations, Assessment, Development and Evaluation, respectively.

Ethics and dissemination

Ethical approval was not required because of the nature of this study. Findings will be disseminated through peer-reviewed publications, conference presentations and through clinical rehabilitation networks.

PROSPERO registration number

CRD42022343290.
Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis
Authors: Alemu Ayinalem , Bitew Zebenay Workneh , Diriba Getu , Gashu Emebet , Seid Getachew , Eshetu Kirubel , Kebede Abebaw , Gumi Balako
Published: April 2023

Introduction

To date, acquired resistance to second-line antituberculosis drugs (SLDs) during multi-drug resistant tuberculosis (MDR-TB) treatment is becoming a public health concern. Different studies have assessed the incidence of acquired resistance to SLDs. However, the findings are inconsistent and there is limited global evidence. Thus, we are going to assess the incidence and predictors of acquired resistance to SLDs during MDR-TB treatment.

Methods and analysis

We designed this protocol following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Electronic databases and grey literature sources will be searched systematically for articles published up to 25 March 2023. Studies reporting the incidence and predictors of acquired resistance to SLDs in MDR-TB patients will be explored. The studies will be managed using Endnote X8 citation manager and a stepwise approach will be followed to select studies. Data will be summarised using Microsoft Excel 2016 spreadsheet. A Newcastle-Ottawa Scale quality assessment and cochrane risk-of-bias tools will be used to assess the study’s quality. The authors will independently search databases, select studies, assess the study’s quality and extract data. Data will be analysed using STATA V.17 software. We will estimate the pooled incidence of acquired resistance with 95% CI. In addition, the pooled effect measures (OR, HR, risk ratio) with their 95% CI will be estimated. Heterogeneity will be assessed using the I2statistics. Publication bias will be assessed using funnel plot and Egger’s test. A subgroup analysis will be conducted for the primary outcome (acquired resistance) per each study characteristics such as WHO regional category, country’s TB/MDR-TB burden, data collection period and per the specific second-line anti-TB drug.

Ethics and dissemination

Since this study will be based on data extraction from published studies, ethical approval is not mandatory. The study will be published in peer-reviewed scientific journals and the findings will be presented at different scientific conferences.

PROSPERO registration number

CRD42022371014.
Infection-related hospitalisation in young adults with systemic lupus erythematosus: data from the National Inpatient Sample
Authors: Dhital Rashmi , Guma Monica , Poudel Dilli R , Chambers Christina , Kalunian Kenneth
Published: April 2023

Introduction

Care of young adults with SLE (YA-SLE, 18–24 years) is challenging due to major life transitions co-occurring with chronic healthcare needs. Studies have demonstrated poorer outcomes in the post-transition period. Epidemiological studies focused on serious infection-related hospitalisation (SIH) in YA-SLE are lacking.

Methods

We used National Inpatient Sample from 2010 to 2019 to study the epidemiology and outcomes of SIH for five common infections in SLE, namely sepsis, pneumonia, urinary tract infections, skin and soft tissue infections, and opportunistic infections. For time trends, we extended the dataset to cover 2000–2019. The primary outcome was the rate of SIH in YA-SLE compared with adults (25–44 years) with SLE and with young adults without SLE (YA-no SLE).

Results

From 2010 to 2019, we identified 1 720 883 hospital admissions with SLE in patients aged ≥18 years. Rates of SIH were similar in young adults and adults with SLE (15.0% vs 14.5%, p=0.12), but considerably higher than in the YA-no SLE group (4.2%, p<0.001). Among SLE with SIH, sepsis followed by pneumonia was the most common diagnosis. Significantly higher proportions of SIH among young adults than adults with SLE were comprised of non-white patients, belonged to the lowest income quartile and had Medicaid. However, only race/ethnicity was associated with SIH among YA-SLE. There was a higher prevalence of comorbid lupus nephritis and pleuritis among young adults compared with adults with SLE and SIH, and both comorbidities were associated with SIH in YA-SLE. Increasing rates of SIH, driven by sepsis, were seen over time.

Discussion

YA- SLE had similar rates of SIH to adults with SLE. While hospitalised YA-SLE differed sociodemographically from SLE adults and YA-no SLE, only race/ethnicity was associated with SIH in the YA-SLE group. Lupus nephritis and pleuritis were associated with higher SIH in YA-SLE. Among SLE with SIH, increasing trends of sepsis deserve further study.
What neurologists can do for neuro-oncology patients
Authors: McKevitt Fiona M
Published: April 2023

Neuro-oncology is a branch of medical science concerned with managing central nervous system tumours and neurological complications of cancer. Patients with brain tumours need a multidisciplinary approach to their care and neurologists can play a key part within that team. This review shows how neurologists can contribute to the care of patients with neuro-oncological disease at various points during the illness, including at initial diagnosis, during symptom management and at end of life assisting with palliative seizure management. The review focuses on brain tumour-related epilepsy, the complications of brain tumour treatments and the neurological complications of systemic cancer treatments including immunotherapies.
Synthesis and properties of 5,10-calixphyrin and its palladium-inserted complex
Authors: Kang Zhengxin , Wang Long , Li Zhongxin , Wu Qinghua , Wei Ying , Zuo Huiquan , Hao Erhong , Jiao Lijuan
Published: April 2023

The reaction of dipyrrolomethane and acetone in the presence of acid and oxidant affords a mixture of 5,15-calixphyrin and 5,10-calixphyrin. The 5,10-calixphyrin readily forms an organometallic Pd(II) complex in 84% yield when treated with Pd(OAc)2 in acetonitrile at reflux. The crystal structure revealed that the 5,10-calixphyrin macrocycle adopted a twisted conformation because of the existence of two sp3-hybridized meso-carbon atoms, which was an impediment in [Formula: see text]-delocalization throughout the macrocycle core. The optimized palladium complex displayed a tetrahedron geometry with reduced distortion throughout the macrocycle. The introduction of palladium metal to the parent calixphyrin scaffold was found to have profound effects on the photophysical and electrochemical properties. Significantly, palladium-inserted 5,10-calixphyrin complex exhibits favorable absorption bands in the visible-near-infrared region with a maximum peak at 672 nm, which is a 148 nm red-shift as compared with that of free base 5,10-calixphyrin. The Pd(II) complex exhibits two reversible reductions and two irreversible oxidations and is more electron-deficient than the corresponding free-base 5,10-calixphyrin. Time-dependent density functional theory studies supported the experimental observations.
Synthesis and optical properties of 3,5-bis(10-phenylanthracen-9-yl)benzene-appended porphyrins
Authors: Umemiya Akane , Nakano Haruyuki , Iwaya Nanami , Ikoma Tadaaki , Matano Yoshihiro
Published: April 2023

Singlet–singlet and triplet-triplet energy-transfer processes between anthracenes and porphyrins have received considerable attention in materials chemistry. Herein, we report the first examples of 3,5-bis(10-phenylanthracen-9-yl)benzene-appended porphyrins (BPABPs) designed to study intramolecular energy transfer between two chromophores. The Curtius rearrangement of 3,5-bis(10-phenylanthracen-9-yl)benzoyl azide in the presence of the platinum(II) complex of 5,10,15-tris(3,5-di-tert-butylphenyl)-20-(3-hydroxyphenyl)porphyrin or its free base in toluene afforded the corresponding BPABP. Spectroscopy, cyclic voltammetry, and density functional theory calculations revealed that the anthracene and porphyrin [Formula: see text]-electron systems of the BPABPs are not conjugated and consequently do not affect each other’s absorption properties. In contrast, the BPABPs exhibited considerably different luminescence properties to those of phenyl 3,5-bis(10-phenylanthracen-9-yl)carbamate and 5,10,15-tris(3,5-di-tert-butylphenyl)-20-(3-methoxyphenyl)porphyrins; the anthracene units of the BPABPs show considerably quenched fluorescence compared to that of the reference anthracene, indicative of efficient intramolecular singlet–singlet energy transfer from the anthracene to the porphyrin unit. The phosphorescence quantum yield of the Pt complex of BPABP is comparable to that of the reference Pt-porphyrin, which suggests that intramolecular triplet-triplet energy transfer from the Pt-porphyrin to the anthracene unit is inefficient. The present findings improve our understanding of how structural factors and excited-state energy levels affect energy transfer and triplet-triplet annihilation upconversion processes of covalently linked bisanthracene-appended porphyrins.
Deep Brain Stimulation for Obsessive-Compulsive Disorder and Depression
Authors: Sheth Sameer A. , Mayberg Helen S.
Published: April 2023

The field of stereotactic neurosurgery developed more than 70 years ago to address a therapy gap for patients with severe psychiatric disorders. In the decades since, it has matured tremendously, benefiting from advances in clinical and basic sciences. Deep brain stimulation (DBS) for severe, treatment-resistant psychiatric disorders is currently poised to transition from a stage of empiricism to one increasingly rooted in scientific discovery. Current drivers of this transition are advances in neuroimaging, but rapidly emerging ones are neurophysiological—as we understand more about the neural basis of these disorders, we will more successfully be able to use interventions such as invasive stimulation to restore dysfunctional circuits to health. Paralleling this transition is a steady increase in the consistency and quality of outcome data. Here, we focus on obsessive-compulsive disorder and depression, two topics that have received the most attention in terms of trial volume and scientific effort.
Emerging Pathogenic Viral Infections of the Eye
Authors: Rishi Ekta , Thomas Joanne , Fashina Tolulope , Kim Lucas , Yeh Steven
Published: April 2023

Global health security threats and the public health impact resulting from emerging infectious diseases including the ongoing COVID-19 pandemic and recent Ebola virus disease outbreaks continuously emphasize the need for a comprehensive approach to preparedness, management of disease outbreaks, and health sequelae associated with emergent pathogens. A spectrum of associated ophthalmic manifestations, along with the potential persistence of emerging viral pathogens in ocular tissues, highlight the importance of an ophthalmic approach to contributing to efforts in the response to public health emergencies from disease outbreaks. This article summarizes the ophthalmic and systemic findings, epidemiology, and therapeutics for emerging viral pathogens identified by the World Health Organization as high-priority pathogens with epidemic potential.
Binocular 3-D otolith-ocular reflexes: responses of chinchillas to natural and prosthetic stimulation after ototoxic injury and vestibular implantation
Authors: Chow Margaret R. , Fernandez Brillet Celia , Hageman Kristin N. , Roberts Dale C. , Ayiotis Andrianna I. , Haque Razi M. , Della Santina Charles C.
Published: April 2023

Previous studies to expand the scope of prosthetic stimulation of the otolith end organs showed that selective stimulation of the utricle and saccule is possible. This article further defines those possibilities by characterizing a diseased animal model and subsequently studying its responses to electrical stimulation alone and in combination with mechanical motion. We show that we can partially restore responses to tilt and translation in animals with unilateral gentamicin ototoxic injury and contralateral surgical disruption.
Effect of Layered Debranning Processing on the Proximate Composition, Polyphenol Content, and Antioxidant Activity of Whole Grain Wheat
Authors: Guan Wenwen , Zhang Duqin , Tan Bin
Published: April 2023

Layered debranning processing (LDP) of whole grain wheat (WGW) could not only retain more bioactive compounds but also contributes to grain saving policy as compared with the refined wheat flour (WF). In this study, effect of different debranning rates from 0 to 13.37% on the proximate composition, polyphenol content, and the antioxidant activity were analyzed. As debranning rates increased from 0 to 13.37%, the insoluble dietary fiber content decreased from 9.94% to 6.47%, whereas the soluble dietary fiber contents increased from 3.06% to 3.98%. The free phenolic content decreased by 62.72%, while the free flavonoid content increased by 4.68% with debranning rates increasing. For the phenolic acids, protocatechuic acid and ferulic acid dominated the free and bound phenolic acid in WGW, which showed the highest contents at 6.95% and 4.45% debranning rates, respectively. As for flavonoids, naringenin (the free-state phenolic) and rutin (the bound state phenolic) in WGW had the greatest level at 4.45% debranning rate. As compared to WGW and WF, LDP significantly improved the DPPH, ABTS·+ radical scavenging activities and total antioxidant activities. In conclusion, 4.45% and 6.95% were the best debranning rates to retain polyphenol contents and antioxidant activities.
Supplementary Data from Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
Authors: Calvo-Vidal M. Nieves , Zamponi Nahuel , Krumsiek Jan , Stockslager Max A. , Revuelta Maria V. , Phillip Jude M. , Marullo Rossella , Tikhonova Ekaterina , Kotlov Nikita , Patel Jayeshkumar , Yang Shao Ning , Yang Lucy , Taldone Tony , Thieblemont Catherine , Leonard John P. , Martin Peter , Inghirami Giorgio , Chiosis Gabriela , Manalis Scott R. , Cerchietti Leandro
Published: April 2023

Supplementary Table 1, Table 2 and Table 3
Figure S4 from Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
Authors: Saltari Annalisa , Dzung Andreas , Quadri Marika , Tiso Natascia , Facchinello Nicola , Hernández-Barranco Alberto , Garcia-Silva Susana , Nogués Laura , Stoffel Corinne Isabelle , Cheng Phil F. , Turko Patrick , Eichhoff Ossia M. , Truzzi Francesca , Marconi Alessandra , Pincelli Carlo , Peinado Héctor , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

Evaluation of AÎ²(25-35) in 3D spheroids and zebrafish larvae
Figure S3 from Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
Authors: Saltari Annalisa , Dzung Andreas , Quadri Marika , Tiso Natascia , Facchinello Nicola , Hernández-Barranco Alberto , Garcia-Silva Susana , Nogués Laura , Stoffel Corinne Isabelle , Cheng Phil F. , Turko Patrick , Eichhoff Ossia M. , Truzzi Francesca , Marconi Alessandra , Pincelli Carlo , Peinado Héctor , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

Evaluation of AÎ² (25-35) in ex vivo cultures
Figure S1 from Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
Authors: Saltari Annalisa , Dzung Andreas , Quadri Marika , Tiso Natascia , Facchinello Nicola , Hernández-Barranco Alberto , Garcia-Silva Susana , Nogués Laura , Stoffel Corinne Isabelle , Cheng Phil F. , Turko Patrick , Eichhoff Ossia M. , Truzzi Francesca , Marconi Alessandra , Pincelli Carlo , Peinado Héctor , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

Evaluation of the role of CD271 in drug resistance
Data from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Authors: Zhao Mengjie , Li Yanhui , Lu Chenfei , Ding Fangshu , Xu Miao , Ge Xin , Li Mengdie , Wang Zhen , Yin Jianxing , Zhang Junxia , Wang Xiefeng , Ge Zehe , Xiao Hong , Xiao Yong , Liu Hongyi , Liu Wentao , Cao Yuandong , Wang Qianghu , You Yongping , Wang Xiuxing , Yang Kun , Shi Zhumei , Qian Xu
Published: April 2023

Abstract
Radiotherapy is a major component of standard-of-care treatment for gliomas, the most prevalent type of brain tumor. However, resistance to radiotherapy remains a major concern. Identification of mechanisms governing radioresistance in gliomas could reveal improved therapeutic strategies for treating patients. Here, we report that mitochondrial metabolic pathways are suppressed in radioresistant gliomas through integrated analyses of transcriptomic data from glioma specimens and cell lines. Decreased expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α), the key regulator of mitochondrial biogenesis and metabolism, correlated with glioma recurrence and predicted poor prognosis and response to radiotherapy of patients with glioma. The subpopulation of glioma cells with low-mitochondrial-mass exhibited reduced expression of PGC1α and enhanced resistance to radiotherapy treatment. Mechanistically, PGC1α was phosphorylated at serine (S) 636 by DNA-dependent protein kinase in response to irradiation. Phosphorylation at S636 promoted the degradation of PGC1α by facilitating its binding to the E3 ligase RNF34. Restoring PGC1α activity with expression of PGC1α S636A, a phosphorylation-resistant mutant, or a small-molecule PGC1α activator ZLN005 increased radiosensitivity of resistant glioma cells by reactivating mitochondria-related reactive oxygen species production and inducing apoptotic effects both in vitro and in vivo. In summary, this study identified a self-protective mechanism in glioma cells in which radiotherapy-induced degradation of PGC1α and suppression of mitochondrial biogenesis play a central role. Targeted activation of PGC1α could help improve response to radiotherapy in patients with glioma.
Significance:
Glioma cells reduce mitochondrial biogenesis by promoting PGC1α degradation to promote resistance to radiotherapy, indicating potential therapeutic strategies to enhance radiosensitivity.
Data from Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients
Authors: Woitek Ramona , McLean Mary A. , Ursprung Stephan , Rueda Oscar M. , Manzano Garcia Raquel , Locke Matthew J. , Beer Lucian , Baxter Gabrielle , Rundo Leonardo , Provenzano Elena , Kaggie Joshua , Patterson Andrew , Frary Amy , Field-Rayner Johanna , Papalouka Vasiliki , Kane Justine , Benjamin Arnold J.V. , Gill Andrew B. , Priest Andrew N. , Lewis David Y. , Russell Roslin , Grimmer Ashley , White Brian , Latimer-Bowman Beth , Patterson Ilse , Schiller Amy , Carmo Bruno , Slough Rhys , Lanz Titus , Wason James , Schulte Rolf F. , Chin Suet-Feung , Graves Martin J. , Gilbert Fiona J. , Abraham Jean E. , Caldas Carlos , Brindle Kevin M. , Sala Evis , Gallagher Ferdia A.
Published: April 2023

Abstract
Hyperpolarized 13C-MRI is an emerging tool for probing tissue metabolism by measuring 13C-label exchange between intravenously injected hyperpolarized [1–13C]pyruvate and endogenous tissue lactate. Here, we demonstrate that hyperpolarized 13C-MRI can be used to detect early response to neoadjuvant therapy in breast cancer. Seven patients underwent multiparametric 1H-MRI and hyperpolarized 13C-MRI before and 7–11 days after commencing treatment. An increase in the lactate-to-pyruvate ratio of approximately 20% identified three patients who, following 5–6 cycles of treatment, showed pathological complete response. This ratio correlated with gene expression of the pyruvate transporter MCT1 and lactate dehydrogenase A (LDHA), the enzyme catalyzing label exchange between pyruvate and lactate. Analysis of approximately 2,000 breast tumors showed that overexpression of LDHA and the hypoxia marker CAIX was associated with reduced relapse-free and overall survival. Hyperpolarized 13C-MRI represents a promising method for monitoring very early treatment response in breast cancer and has demonstrated prognostic potential.
Significance:
Hyperpolarized carbon-13 MRI allows response assessment in patients with breast cancer after 7–11 days of neoadjuvant chemotherapy and outperformed state-of-the-art and research quantitative proton MRI techniques.
Supplementary Figure Legends 1-5 from Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Authors: Ewton Daina Z. , Hu Jing , Vilenchik Maria , Deng Xiaobing , Luk Kin-chun , Polonskaia Ann , Hoffman Ann F. , Zipf Karen , Boylan John F. , Friedman Eileen A.
Published: April 2023

PDF file - 57K
Supplementary Figure 1 from Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Authors: Ewton Daina Z. , Hu Jing , Vilenchik Maria , Deng Xiaobing , Luk Kin-chun , Polonskaia Ann , Hoffman Ann F. , Zipf Karen , Boylan John F. , Friedman Eileen A.
Published: April 2023

PDF file - 387K
Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Authors: Chen Chun-Te , Yamaguchi Hirohito , Lee Hong-Jen , Du Yi , Lee Heng-Huan , Xia Weiya , Yu Wen-Hsuan , Hsu Jennifer L. , Yen Chia-Jui , Sun Hui-Lung , Wang Yan , Yeh Edward T.H. , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Authors: Chen Chun-Te , Yamaguchi Hirohito , Lee Hong-Jen , Du Yi , Lee Heng-Huan , Xia Weiya , Yu Wen-Hsuan , Hsu Jennifer L. , Yen Chia-Jui , Sun Hui-Lung , Wang Yan , Yeh Edward T.H. , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Supplementary Figure 1 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Authors: Liu Li , Shi Hong , Liu Yuan , Anderson Amber , Peterson John , Greger James , Martin Anne-Marie , Gilmer Tona M.
Published: April 2023

Supplementary Figure 1 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Supplementary Table 3 from Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Authors: Moreaux Jérôme , Rème Thierry , Leonard Wim , Veyrune Jean-Luc , Requirand Guilhem , Goldschmidt Hartmut , Hose Dirk , Klein Bernard
Published: April 2023

PDF file - 40K, Genes overexpressed in decitabine treated HMCLs. Five HMCLs were cultured with or without 0.5 μM decitabine for 7 days and gene expression was profiled with Affymetrix U133 plus 2.0. Genes significantly differentially expressed between control and decitabine treated cells were identified using SAM supervised paired analysis with a 5% false discovery rate. When a gene was interrogated by several probe sets, we used the probe set yielding to a maximum variance across control and decitabine treated cells.
Supplementary Figure 1 from Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Authors: Moreaux Jérôme , Rème Thierry , Leonard Wim , Veyrune Jean-Luc , Requirand Guilhem , Goldschmidt Hartmut , Hose Dirk , Klein Bernard
Published: April 2023

PDF file - 3577K, (A) Highest confidence networks of genes deregulated by decitabine treatment in HMCLs. (B) According to Ingenuity Pathway Analysis software, the network is relevant to "Interferon signaling". Genes that were deregulated by decitabine in HMCLs are shaded in grey. Each interaction is supported by at least one literature reference with solid lines representing direct interactions and dashed lines representing indirect interactions.
Supplementary Figure Legend from hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Authors: Deville Laure , Hillion Josette , Pendino Frédéric , Samy Mona , Nguyen Eric , Ségal-Bendirdjian Evelyne
Published: April 2023

Supplementary Figure Legend from hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Supplementary Figures 1-3, Tables 1-2 from Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models
Authors: Cheong Jae-Ho , Park Eun Sung , Liang Jiyong , Dennison Jennifer B. , Tsavachidou Dimitra , Nguyen-Charles Catherine , Wa Cheng Kwai , Hall Hassan , Zhang Dong , Lu Yiling , Ravoori Murali , Kundra Vikas , Ajani Jaffer , Lee Ju-Seog , Ki Hong Waun , Mills Gordon B.
Published: April 2023

PDF file - 1.5MB
Supplementary Figure 5 from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

PDF file, 80K, E-cadh promoter activity in LEF-1 and Slug knockdown clones.
Supplementary Figure 3 from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

PDF file, 97K, HDACs, E-cadh, Ac-Histone H3 and Ac-Histone H4 expression in cells treated with MS-275 with or without CSC.
Supplementary Figure 1 from ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
Authors: Foreman Pamela K. , Gore Medini , Kobel Philip A. , Xu Li , Yee Helena , Hannum Charles , Ho Hoangdung , Wang Sandra M. , Tran Hieu V. , Horowitz Michael , Horowitz Lawrence , Bhatt Ramesh R.
Published: April 2023

PDF file, 50KB, Surrobody Structure.
Supplementary Figure 2 from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Authors: Keating Joanna , Tsoli Maria , Hallahan Andrew R. , Ingram Wendy J. , Haber Michelle , Ziegler David S.
Published: April 2023

PDF file - 257K, Treatment with irradiation and LBW242 leads to apoptosis in medulloblastoma cell lines
Supplementary Figure 3 from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
Authors: Bello Ezia , Taraboletti Giulia , Colella Gennaro , Zucchetti Massimo , Forestieri Daniele , Licandro Simonetta A. , Berndt Alexander , Richter Petra , D'Incalci Maurizio , Cavalletti Ennio , Giavazzi Raffaella , Camboni Gabriella , Damia Giovanna
Published: April 2023

PDF file - 41KB, Dose response curve of PTX in MDA-MB-231 cells alone or in combination with E-3810, sunitinb and brivanib.
Supplementary Table 1, Figures 1-2 from CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
Authors: Cheng Mangeng , Quail Matthew R. , Gingrich Diane E. , Ott Gregory R. , Lu Lihui , Wan Weihua , Albom Mark S. , Angeles Thelma S. , Aimone Lisa D. , Cristofani Flavio , Machiorlatti Rodolfo , Abele Cristina , Ator Mark A. , Dorsey Bruce D. , Inghirami Giorgio , Ruggeri Bruce A.
Published: April 2023

PDF file - 300K
Supplementary Figure 3 from CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
Authors: Cheng Mangeng , Quail Matthew R. , Gingrich Diane E. , Ott Gregory R. , Lu Lihui , Wan Weihua , Albom Mark S. , Angeles Thelma S. , Aimone Lisa D. , Cristofani Flavio , Machiorlatti Rodolfo , Abele Cristina , Ator Mark A. , Dorsey Bruce D. , Inghirami Giorgio , Ruggeri Bruce A.
Published: April 2023

PDF file - 102K
Supplementary Methods from Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo
Authors: Wang Hui-Chun , Lee Alan Yueh-Luen , Chou Wen-Cheng , Wu Chin-Chung , Tseng Chao-Neng , Liu Kevin Yen-Ting , Lin Wen-Lien , Chang Fang-Rong , Chuang Da-Wei , Hunyadi Attila , Wu Yang-Chang
Published: April 2023

PDF file, 75KB.
Supplementary Tables 1 and 2 from 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy
Authors: Reber Josefine , Haller Stephanie , Leamon Christopher P. , Müller Cristina
Published: April 2023

PDF - 94KB, Table S1: Complete biodistribution data obtained with 177Lu-EC0800 in KB tumor bearing nude mice. Table S2: Combination indices for 177Lu-EC0800 and PMX determined in vitro using KB and IGROV-1 tumor cells.
Supplementary Figures 1 - 8 from Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo
Authors: Wang Hui-Chun , Lee Alan Yueh-Luen , Chou Wen-Cheng , Wu Chin-Chung , Tseng Chao-Neng , Liu Kevin Yen-Ting , Lin Wen-Lien , Chang Fang-Rong , Chuang Da-Wei , Hunyadi Attila , Wu Yang-Chang
Published: April 2023

PDF file, 984KB.
Supplementary Materials and Methods from 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy
Authors: Reber Josefine , Haller Stephanie , Leamon Christopher P. , Müller Cristina
Published: April 2023

PDF - 128KB, Detailed description of additional methods applied to obtain the results reported in the article.
Supplementary Figures 1-13 from Sorafenib Sensitizes (−)-Gossypol-Induced Growth Suppression in Androgen-Independent Prostate Cancer Cells via Mcl-1 Inhibition and Bak Activation
Authors: Lian Jiqin , Ni Zhenhong , Dai Xufang , Su Chang , Smith Amber Rae , Xu Liang , He Fengtian
Published: April 2023

PDF file - 338K
Supplementary Figure Legend 14 from Sorafenib Sensitizes (−)-Gossypol-Induced Growth Suppression in Androgen-Independent Prostate Cancer Cells via Mcl-1 Inhibition and Bak Activation
Authors: Lian Jiqin , Ni Zhenhong , Dai Xufang , Su Chang , Smith Amber Rae , Xu Liang , He Fengtian
Published: April 2023

PDF file - 49K
Supplementary Figure 4 from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Authors: Gomes-Giacoia Evan , Miyake Makito , Goodison Steve , Rosser Charles J.
Published: April 2023

PDF - 1338KB, A, Annexin V apoptotic assay was performed in parental HeLa cells treated with and without tiplaxtinin (30 and 50 microM) and exposed to the apoptotic inducing agent, mitomycin C at 5 microg/ml. The anti-apoptotic effects of PAI-1 overexpression were abrogated in all cells treated with tiplaxtinin. B, Annexin V apoptotic assay was performed in HeLa clones (HeLa-PAI-1OE and HeLaEmpty) after exposing the cells to the apoptotic inducing agent, mitomycin C at 5 ?g/ml. Overexpression of PAI-1 in HeLa clones elicited protection against mitomycin C induced cell death (HeLa-PAI-1KD-12 and HeLa-PAI-1KD-18). C, Western blot analysis was performed on the above cell lines confirming the induction of the key apoptotic proteins cleaved caspase-3, cleaved-PARP as well as Fas and FasL. Staining for β-actin served as a control. At least three independent experiments consisting of each condition tested in triplicate wells was used to calculate mean + SD values. *, p < 0.05. D, In a cell adhesion assay, treatment of HeLa cells with tiplaxtinin resulted in a dose-dependent reduction in the ability of the cells to adhere to substrate. E, In an anoikis assay, treatment of HeLa cells with tiplaxtinin for 24 hrs resulted in significant induction of anoikis.
Supplementary Figure 3 from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Authors: Gomes-Giacoia Evan , Miyake Makito , Goodison Steve , Rosser Charles J.
Published: April 2023

PDF - 1214KB, A, About 103 HeLa were seeded in 6 well plates exposed to tiplaxtinin at the indicated concentration for 72 hrs followed by aspiration of culture media and replacement with fresh complete media. HeLa clones (HeLa-PAI-1OE-12, HeLa-PAI-1OE-12 and HeLaEmpty control) overexpressing PAI-1 were also plated similarly. Cells were incubated for an additional 14 days. After 14 days, colonies were fixed with 6.0% glutaraldehyde, stained with 0.5% crystal violet and counted under light microscopy. Data were represented as mean + SD of three independent replicates. B, About 2 x 103 HeLa cells pretreated with tiplaxtinin at the indicated concentration and HeLa clones (HeLa-PAI-1OE-12, HeLa-PAI-1OE-12 and HeLaEmpty control) were mixed in agar solution and fresh complete media and seeded in 96-well plates. Cells were incubated for 6-8 days. Colony formation was quantified using the fluorescent cell stain CyQuant GR Dye (Cell Biolabs Inc., San Diego, CA) in the FLUOstar Optima Reader. Data were represented as mean + SD of three independent replicates. All experiments were repeated at least three times. Targeting PAI-1 was noted to retard cellular proliferation and colony formation. *, p < 0.05
Supplementary Figure 1 from Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression
Authors: Bhosle Jaishree , Kiakos Konstantinos , Porter Andrew C.G. , Wu Jenny , Makris Andreas , Hartley John A , Hochhauser Daniel
Published: April 2023

PDF file - 114K, Figure of yH2AX Foci over time following Topo II posion.
Supplementary Table 5 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 85K, Distribution of Eph receptors gene mutations in NSCLC.
Supplementary Table 4 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 77K, Multicovariate Cox model fitted to estimate the effect of age, gender, stage, institution and EphA4 on time to event endpoint, for overall survival.
Supplementary Figure Legend from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 116K.
Supplementary Table 5 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Authors: Kuruma Hidetoshi , Matsumoto Hiroaki , Shiota Masaki , Bishop Jennifer , Lamoureux Francois , Thomas Christian , Briere David , Los Gerrit , Gleave Martin , Fanjul Andrea , Zoubeidi Amina
Published: April 2023

PDF, 56K, MDV3100 and Compound 30 IC50 in MR49F cells
Supplementary Table 7 from Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells
Authors: Allen Wendy L. , Turkington Richard C. , Stevenson Leanne , Carson Gail , Coyle Vicky M. , Hector Suzanne , Dunne Philip , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 11K, Results from KEGG pathway analysis for p53 wild-type and p53 null basal comparison. The table shows the number of genes in each pathway and the p value associated with that pathway calculated using hypergeometric statistics. The pathways that are highlighted in bold are those that are statistically significant (p<0.05).
Supplementary Table 1 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Authors: Kuruma Hidetoshi , Matsumoto Hiroaki , Shiota Masaki , Bishop Jennifer , Lamoureux Francois , Thomas Christian , Briere David , Los Gerrit , Gleave Martin , Fanjul Andrea , Zoubeidi Amina
Published: April 2023

PDF, 49K, AR transcriptional activity EC50 in LNCaP cells treated with MDV3100 and Compound 30
Supplementary Table 4 from Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells
Authors: Allen Wendy L. , Turkington Richard C. , Stevenson Leanne , Carson Gail , Coyle Vicky M. , Hector Suzanne , Dunne Philip , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 214K, List showing 2102 genes that are constitutively altered between isogenic HCT116 p53wild-type and HCT116 p53null cells. Genes have been normalised and filtered as stated in the materials and methods
Supplementary Figure 3 from The Thymidine Phosphorylase Inhibitor 5′-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist
Authors: Liekens Sandra , Bronckaers Annelies , Belleri Mirella , Bugatti Antonella , Sienaert Rebecca , Ribatti Domenico , Nico Beatrice , Gigante Alba , Casanova Elena , Opdenakker Ghislain , Pérez-Pérez María-Jesús , Balzarini Jan , Presta Marco
Published: April 2023

PDF file - 62K
Supplementary Figures 1 - 7 from Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction
Authors: Meyers-Needham Marisa , Lewis Jocelyn A. , Gencer Salih , Sentelle R. David , Saddoughi Sahar A. , Clarke Christopher J. , Hannun Yusuf A. , Norell Haakan , da Palma Telma Martins , Nishimura Michael , Kraveka Jacqueline M. , Khavandgar Zohreh , Murshed Monzur , Cevik M. Ozgur , Ogretmen Besim
Published: April 2023

PDF file, 712KB.
Supplementary Figure 2 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
Authors: Christoph Sandra , DeRyckere Deborah , Schlegel Jennifer , Frazer J. Kimble , Batchelor Lance A. , Trakhimets Alesia Y. , Sather Susan , Hunter Debra M. , Cummings Christopher T. , Liu Jing , Yang Chao , Kireev Dmitri , Simpson Catherine , Norris-Drouin Jacqueline , Hull-Ryde Emily A. , Janzen William P. , Johnson Gary L. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

PDF - 172KB, Jurkat cell cultures were treated with the indicated concentrations of UNC569 for 1 hour. Pervanadate was added to cell cultures for 3 minutes to stabilize the phosphorylated form of Tyro3. Tyro3 was immunoprecipitated from cell lysates and total Tyro3 protein and Tyro3 phosphoprotein (p-Tyro3) were detected by western blot. Numbers on the right indicate the location of molecular weight (kD) markers. Immunoblots are representative of three independent experiments.
Supplementary Figure 2 from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
Authors: Jazaeri Amir A. , Shibata Etsuko , Park Jonghoon , Bryant Jennifer L. , Conaway Mark R. , Modesitt Susan C. , Smith Peter G. , Milhollen Michael A. , Berger Allison J. , Dutta Anindya
Published: April 2023

PDF file, 400K, MLN4924 and cisplatin enhance apoptosis induction in ovarian cancer cells.
Supplementary Figure Legend from Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
Authors: Wu Yaming , Zhang Yixian , Wang Maoliang , Li Qi , Qu Zhengxing , Shi Victoria , Kraft Patricia , Kim Steve , Gao Ying , Pak Jenny , Youngster Stephen , Horak Ivan D. , Greenberger Lee M.
Published: April 2023

Supplementary Figure Legend PDF file - 85K, Figure legend for each supplementary figure.
Supplementary References from Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
Authors: García María J. , Saucedo-Cuevas Laura Paula , Muñoz-Repeto Iván , Fernández Victoria , Robles María J. , Domingo Samuel , Palacios José , Aracil Miguel , Nieto Antonio , Tercero Juan Carlos , Benítez Javier
Published: April 2023

PDF file - 38 KB
Supplementary Figure 1 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Authors: Zhou Yu , Goenaga Anne-Laure , Harms Brian D. , Zou Hao , Lou Jianlong , Conrad Fraser , Adams Gregory P. , Schoeberl Birgit , Nielsen Ulrik B. , Marks James D.
Published: April 2023

PDF file, 450KB, Biphasic distribution of the increase in binding affinity for conversion from monovalent to bivalent forms for antibodies with different intrinsic affinities.
Supplementary Figure Legends from Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
Authors: García María J. , Saucedo-Cuevas Laura Paula , Muñoz-Repeto Iván , Fernández Victoria , Robles María J. , Domingo Samuel , Palacios José , Aracil Miguel , Nieto Antonio , Tercero Juan Carlos , Benítez Javier
Published: April 2023

PDF file - 81 KB
Supplementary Methods, Figures 1-7 from Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
Authors: Sharkey Robert M. , Govindan Serengulam V. , Cardillo Thomas M. , Goldenberg David M.
Published: April 2023

PDF file - 860K
Supplementary Table 2 from The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Authors: Carden Craig P. , Stewart Adam , Thavasu Parames , Kipps Emma , Pope Lorna , Crespo Mateus , Miranda Susana , Attard Gerhardt , Garrett Michelle D. , Clarke Paul A. , Workman Paul , de Bono Johann S. , Gore Martin , Kaye Stan B , Banerji Udai
Published: April 2023

PDF file, 63KB, Survival based on signalling output in total population of 88 patients.
Supplementary Figure Legend from Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Authors: Shao Huanjie , Jing Kai , Mahmoud Esraa , Huang Haihong , Fang Xianjun , Yu Chunrong
Published: April 2023

PDF - 101KB, Legends for Supplemental Figures 1-8.
Supplementary Figures 1 - 3 from STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Authors: Kohsaka Shinji , Wang Lei , Yachi Kazuhiro , Mahabir Roshan , Narita Takuhito , Itoh Tamio , Tanino Mishie , Kimura Taichi , Nishihara Hiroshi , Tanaka Shinya
Published: April 2023

PDF file, 105KB.
Supplementary Figure 2 from Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Authors: Shao Huanjie , Jing Kai , Mahmoud Esraa , Huang Haihong , Fang Xianjun , Yu Chunrong
Published: April 2023

PDF - 678KB, Supplementary Figure S2. Apigenin enhanced ABT-263-triggered cell death in colon cancer cells.
Supplementary Figure 2 from Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Authors: Ninomiya Takashi , Takigawa Nagio , Ichihara Eiki , Ochi Nobuaki , Murakami Toshi , Honda Yoshihiro , Kubo Toshio , Minami Daisuke , Kudo Kenichiro , Tanimoto Mitsune , Kiura Katsuyuki
Published: April 2023

PDF File - 320K, CT images of lungs from transgenic mice with Egfr exon 19 deletion mutation pretreatment (day 0), after 1 week and 4 weeks administration of vehicle or gefitinib (5mg/kg/day) or afatinib (5mg/kg/day).
Supplementary Figure 3 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
Authors: Haider Christine , Grubinger Markus , Řezníčková Eva , Weiss Thomas S. , Rotheneder Hans , Miklos Walter , Berger Walter , Jorda Radek , Zatloukal Marek , Gucký Tomáš , Strnad Miroslav , Kryštof Vladimír , Mikulits Wolfgang
Published: April 2023

PDF file, 228K, Proliferation kinetics of treated hepatoma cells.
Supplementary Figure 1 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
Authors: Haider Christine , Grubinger Markus , Řezníčková Eva , Weiss Thomas S. , Rotheneder Hans , Miklos Walter , Berger Walter , Jorda Radek , Zatloukal Marek , Gucký Tomáš , Strnad Miroslav , Kryštof Vladimír , Mikulits Wolfgang
Published: April 2023

PDF file, 97K, Chemical structure of BA-12 and BP-14.
Supplementary Materials and Methods from Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Authors: Vosjan Maria J.W.D. , Vercammen Jo , Kolkman Joost A. , Stigter-van Walsum Marijke , Revets Hilde , van Dongen Guus A.M.S.
Published: April 2023

PDF file - 78K
Supplementary Figure S6 from Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Authors: Sumi Hiroyuki , Yabuki Masato , Iwai Kenichi , Morimoto Megumi , Hibino Ryosuke , Inazuka Masakazu , Hashimoto Kentaro , Kosugi Yohei , Aoyama Kazunobu , Yamamoto Shunsuke , Yoshimatsu Mie , Yamasaki Hideki , Tozawa Ryuichi , Ishikawa Tomoyasu , Yoshida Sei
Published: April 2023

PDF file - 195KB, In vivo antitumor effect of T-3256336 in HL-60 xenograft models
Supplementary Table from EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas
Authors: Basu Devraj , Bewley Arnaud F. , Sperry Steven M. , Montone Kathleen T. , Gimotty Phyllis A. , Rasanen Kati , Facompre Nicole D. , Weinstein Gregory S. , Nakagawa Hiroshi , Diehl J. Alan , Rustgi Anil K. , Herlyn Meenhard
Published: April 2023

PDF file, 69K, Clinical and pathologic features of 10 human head and neck SCCs grouped by pattern of invasion.